Crohn's PRO-2 Score: The Symptoms Behind the Number

Crohn’s PRO-2 is a patient-reported outcome built from two symptoms: abdominal pain and the number of very soft or liquid stools. It is most often encountered in clinical-trial results, where it offers a focused way to measure whether patients feel better without adding a clinician’s judgment or a lab result. The simplicity is intentional, but it creates an important limit: PRO-2 does not contain CRP, fecal calprotectin, imaging, or endoscopy. Trial programs therefore often report symptom improvement and objective bowel improvement as separate outcomes (CORE-IBD consensus; STRIDE-II).

The two PRO-2 inputs

The abdominal-pain item is generally recorded on an ordered scale, while stool frequency is a count of very soft or liquid stools. Data are commonly collected daily in an electronic diary and summarized over a defined period. The exact formula, averaging window, weighting, and remission threshold can depend on the trial. This is why a study’s methods section matters more than a standalone online calculator.

PRO-2 was derived from patient-reported parts of the CDAI. It removes clinician-assessed and laboratory elements so the endpoint focuses on what the patient directly experiences. That makes it less burdensome than the full CDAI and easier to collect repeatedly. It also means PRO-2 is not the same as HBI, which includes well-being, an abdominal-mass assessment, and complications. Trial data show that PRO-2 and HBI correlate strongly at the group level, yet estimates for an individual can still span a wide range (HBI estimated from PRO-2).

UC also has a measure called PRO-2, but it uses stool frequency and rectal bleeding rather than abdominal pain. Always confirm the disease and protocol before interpreting the term.

What “PRO-2 remission” means

PRO-2 remission means the two recorded symptoms met a study’s prespecified low thresholds. In one phase 3 Crohn’s analysis, the remission definition used an abdominal-pain score of 1 or less and average daily stool frequency of 1.5 or less, but definitions and calculation details should be checked in each protocol (trial endpoint analysis). The decimal does not mean a person had half a bowel movement; it usually reflects an average across several diary days.

A lower PRO-2 can be genuinely meaningful because pain and diarrhea strongly affect daily life. It still does not establish that ulcers have healed. Research comparing PRO-2 with the SES-CD endoscopy score found only modest correlation and differences related to disease location (PRO-2 and SES-CD study). Another prospective evaluation examined relationships among PRO measures, endoscopic activity, and other outcomes, reinforcing that symptom endpoints need validation against the particular target being studied (prospective PRO study).

Where labs and scopes fit

CRP and fecal calprotectin are not mathematical inputs to PRO-2. They can be reported beside it as objective evidence, along with an endoscopic score such as SES-CD. A treatment trial may use co-primary endpoints, requiring both symptom remission and endoscopic response. Clinical practice can use a similar layered idea without reproducing the trial formula: track what you feel, test for inflammation when appropriate, and investigate disagreement rather than assuming one result cancels the other.

AGA guidance recommends combining symptoms with biomarker results in Crohn’s disease monitoring (AGA Crohn’s biomarker guidance). If pain and stool frequency improve while calprotectin remains elevated, your clinician may consider timing, infection, medication exposure, disease location, or direct bowel assessment. If symptoms persist while objective inflammation is controlled, other causes of pain or diarrhea may need evaluation.

For appointments or trial screening, keep the diary definition consistent and record days affected by bowel preparation, infection, travel, or missed entries. Save the score beside medication dates, CRP, calprotectin, and endoscopy results. PRO-2 gives the patient’s experience a formal place in the evidence. Its value comes from knowing exactly what that small number captures, and what it deliberately leaves for other measures. Before comparing studies, check the averaging window, handling of missing diary days, symptom scale, remission thresholds, and assessment week. Ask whether the reported endpoint required PRO-2 alone or combined it with endoscopic response. For your own trend, preserve the daily pain ratings and stool counts rather than only the final average. The component diary can reveal whether improvement came mainly from less pain, fewer liquid stools, or both, which is more informative than a total without context.

Record the treatment date too, so the relationship between the intervention and the symptom-assessment window remains clear during later comparisons.